176 related articles for article (PubMed ID: 11304511)
1. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Lüscher TF
Hypertension; 2001 Apr; 37(4):1108-13. PubMed ID: 11304511
[TBL] [Abstract][Full Text] [Related]
2. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
[TBL] [Abstract][Full Text] [Related]
3. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats.
Ying L; Flamant M; Vandermeersch S; Boffa JJ; Chatziantoniou C; Dussaule JC; Chansel D
Hypertension; 2003 Nov; 42(5):937-44. PubMed ID: 14569001
[TBL] [Abstract][Full Text] [Related]
4. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
5. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension.
Quaschning T; D'Uscio LV; Shaw S; Gröne HJ; Ruschitzka F; Lüscher TF
J Am Soc Nephrol; 2001 Nov; 12(11):2280-2287. PubMed ID: 11675404
[TBL] [Abstract][Full Text] [Related]
6. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.
Intengan HD; Schiffrin EL
Hypertension; 2000 Jun; 35(6):1221-5. PubMed ID: 10856267
[TBL] [Abstract][Full Text] [Related]
7. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
8. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
[TBL] [Abstract][Full Text] [Related]
9. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Pu Q; Amiri F; Gannon P; Schiffrin EL
J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
[TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
Quaschning T; Hocher B; Ruhl S; Kraemer-Guth A; Tilgner J; Wanner C; Galle J
Kidney Blood Press Res; 2006; 29(6):351-9. PubMed ID: 17139187
[TBL] [Abstract][Full Text] [Related]
11. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats.
Cheng ZJ; Grönholm T; Louhelainen M; Finckenberg P; Merasto S; Tikkanen I; Mervaala E
J Hypertens; 2005 Sep; 23(9):1757-70. PubMed ID: 16093923
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension.
Millette E; Demeilliers B; Wu R; Laplante MA; El Midaoui A; Moreau P; Lamontagne D; de Champlain J
J Hypertens; 2003 Jan; 21(1):125-35. PubMed ID: 12544444
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
[TBL] [Abstract][Full Text] [Related]
15. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
[TBL] [Abstract][Full Text] [Related]
16. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.
Mitchell GF; Izzo JL; Lacourcière Y; Ouellet JP; Neutel J; Qian C; Kerwin LJ; Block AJ; Pfeffer MA
Circulation; 2002 Jun; 105(25):2955-61. PubMed ID: 12081987
[TBL] [Abstract][Full Text] [Related]
17. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
Elmarakby AA; Morsing P; Pollock JS; Pollock DM
Vascul Pharmacol; 2003 Dec; 40(5):253-9. PubMed ID: 15259792
[TBL] [Abstract][Full Text] [Related]
18. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
[TBL] [Abstract][Full Text] [Related]
19. Role of endothelin B receptors in enhancing endothelium-dependent nitric oxide-mediated vascular relaxation during high salt diet.
Giardina JB; Green GM; Rinewalt AN; Granger JP; Khalil RA
Hypertension; 2001 Feb; 37(2 Pt 2):516-23. PubMed ID: 11230328
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
